Spain’s SpliceBio Defies Sentiment With €50m Financing

Gene Therapy Player Backed By UCB And Novartis

The Barcelona-based firm, which has a protein splicing platform that aims to address the major limitation of delivering large genes using AAV vectors, has sealed the largest series A fundraising by a Spanish biotech.

Vila-Perelló 1200
Miquel Vila-Perelló • Source: SpliceBio

Gene therapy is hardly flavor of the month for investors at the moment but that has not stopped SpliceBio from signing off the largest ever series A financing in Spain for a biotech company.

SpliceBio has completed an oversubscribed €50m finance round co-led by UCB Ventures and existing shareholder Ysios Capital

More from Financing

More from Business